Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 743 results found since Jan 2013.

Immunotherapy for Sepsis Induced by Infections: Clinical Evidence and Potential Targets
Discov Med. 2022 Sep-Oct;34(172):83-95.ABSTRACTSepsis is a life-threatening organ dysfunction caused by the maladjustment of the body's response to infection. Abnormal immune response plays an important role in the progression of sepsis, and immunomodulatory therapy is a promising therapeutic strategy for sepsis. Great efforts have been made recently to elucidate the mechanism by which immune dysfunction contributes to sepsis, and identify potential biomarkers and targets for the diagnosis and therapy of sepsis induced by emerging pathogens, especially for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)that ca...
Source: Discovery Medicine - October 25, 2022 Category: Research Authors: Sheng-Jie Huang Tao Ai Hui Hu Juan Wang Jin-Long Wang Source Type: research

Lung cancer and oncolytic virotherapy--enemy's enemy
This article provides a comprehensive review of the latest progress in oncolytic virotherapy for lung cancer, including the specific mechanism of oncolytic virus therapy and the main types of oncolytic viruses, and the combination of oncolytic virotherapy and existing standard treatments. It aims to provide new insights and ideas on oncolytic virotherapy for lung cancer.PMID:36244134 | DOI:10.1016/j.tranon.2022.101563
Source: Translational Oncology - October 16, 2022 Category: Cancer & Oncology Authors: Zhang Li Zhang Feiyue Li Gaofeng Liang Haifeng Source Type: research

SARS CoV-2 infections in animals, two years into the pandemic
AbstractIn December 2019, several cases of pneumonia caused by a novel coronavirus, later identified as SARS-CoV-2, were detected in the Chinese city of Wuhan. Due to its rapid worldwide spread, on 11 March 2020 the World Health Organization declared a pandemic state. Since this new virus is genetically similar to the coronaviruses of bats, SARS-CoV-2 was hypothesized to have a zoonotic origin. Within a year of the appearance of SARS-CoV-2, several cases of infection were also reported in animals, suggesting human-to-animal and animal-to-animal transmission among mammals. Natural infection has been found in companion anima...
Source: Archives of Virology - October 7, 2022 Category: Virology Source Type: research

A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs). The coronavirus disease 2019 (COVID-19) is associated with increased amounts of pro-inflammatory cytokines, which may affect the outcome of irAEs. Data are limited regarding the impact of COVID-19 on irAEs in ICI-treated cancer patients. Hence, in this study, we retrospectively analyzed ICI-treated adult patients with malignant solid tumors at a single institution between August 2020 and August 2021. Patients who had the most recent ICI treatment over 1-month before or after the positive COVID-19 test were excluded from the st...
Source: Journal of Immunotherapy - October 6, 2022 Category: Allergy & Immunology Tags: Clinical Studies Source Type: research

Distinct responses of newly identified monocyte subsets to advanced gastrointestinal cancer and COVID-19
Monocytes are critical cells of the immune system but their role as effectors is relatively poorly understood, as they have long been considered only as precursors of tissue macrophages or dendritic cells. Moreover, it is known that this cell type is heterogeneous, but our understanding of this aspect is limited to the broad classification in classical/intermediate/non-classical monocytes, commonly based on their expression of only two markers, i.e. CD14 and CD16. We deeply dissected the heterogeneity of human circulating monocytes in healthy donors by transcriptomic analysis at single-cell level and identified 9 distinct ...
Source: Frontiers in Immunology - October 3, 2022 Category: Allergy & Immunology Source Type: research

Viruses, Vol. 14, Pages 2180: Pin-Pointing the Key Hubs in the IFN- & gamma; Pathway Responding to SARS-CoV-2 Infection
Viruses, Vol. 14, Pages 2180: Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection Viruses doi: 10.3390/v14102180 Authors: Ayelen Toro Sofia Lage-Vickers Juan Bizzotto Felipe Vilicich Agustina Sabater Gaston Pascual Sabrina Ledesma-Bazan Pablo Sanchis Maria Sol Ruiz Ana Paula Arevalo Jorge L. Porfido Mercedes Abbate Rocio Seniuk Estefania Labanca Nicolas Anselmino Nora M. Navone Daniel F. Alonso Elba Vazquez Martina Crispo Javier Cotignola Geraldine Gueron Interferon gamma (IFN-γ) may be potential adjuvant immunotherapy for...
Source: Viruses - September 30, 2022 Category: Virology Authors: Ayelen Toro Sofia Lage-Vickers Juan Bizzotto Felipe Vilicich Agustina Sabater Gaston Pascual Sabrina Ledesma-Bazan Pablo Sanchis Maria Sol Ruiz Ana Paula Arevalo Jorge L. Porfido Mercedes Abbate Rocio Seniuk Estefania Labanca Nicolas Anselmino Nora M. Nav Tags: Article Source Type: research

Potential of mRNA vaccines to become versatile cancer vaccines
World J Clin Oncol. 2022 Aug 24;13(8):663-674. doi: 10.5306/wjco.v13.i8.663.ABSTRACTFor centuries, therapeutic cancer vaccines have been developed and tried clinically. Way back in the late 19th century, the Father of Immunotherapy, William Coley had discovered that bacterial toxins were effective for inoperable sarcomas. In the 1970s, the Bacillus Calmette-Guérin (BCG) vaccine was repurposed, e.g., for advanced melanomas. Then, therapeutic cancer vaccines based on tumor-associated antigens (found on the surfaces of cancer cells) were tried clinically but apparently have not made a really significant clinical impact. For ...
Source: Clinical Prostate Cancer - September 26, 2022 Category: Cancer & Oncology Authors: Shiu-Ying Tsao Source Type: research

Cancers, Vol. 14, Pages 4642: Recall Radiation Pneumonitis: A Rare Syndrome That Should Be Recognized
En Wu Recall radiation pneumonitis (RRP) is a rare but severe condition which has been mainly detected in the previously irradiated lung of patients with cancer after administering inciting agents, most commonly antineoplastic regimens including chemotherapy, targeted therapy, or immunotherapy. More recently, coronavirus disease vaccines were found to induce RRP. In addition to typical radiation pneumonitis (RP) or drug-induced interstitial lung disease, the management of RRP requires withholding inciting agents and steroid therapy. Thus, the occurrence of RRP could significantly impact cancer treatment, given that inc...
Source: Cancers - September 24, 2022 Category: Cancer & Oncology Authors: Pei-Rung Jan John Wen-Cheng Chang Chiao-En Wu Tags: Review Source Type: research